Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 6/20 | 0.81 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.81 |
| ▸ | AVPR1B known ✓ | P47901 | 4/20 | 0.81 |
| ▸ | OXTR | P30559 | 9/20 | 0.81 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.81 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL4642385 | 1.00 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL28142694 | 1.00 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL204511 | 0.99 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL6021294 | 0.99 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29354819 | 0.99 | OXTR (0.82) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL23382246 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL15933169 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL2687079 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL21131126 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL10053268 | 0.98 | OXTR (0.85) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2026-05-07 | — | — | US | disclosed |
| US-20250241977-A1 | SAFE DESMOPRESSIN ADMINISTRATION | ACERUS PHARMACEUTICALS USA LLC (US) | 2025-07-31 | — | — | US | disclosed |
| US-12357573-B2 | Pharmaceutical composition for drug delivery | OREXO AB (SE) | 2025-07-15 | — | — | US | disclosed |
| EP-2442821-B2 | SAFE DESMOPRESSIN ADMINISTRATION | ACERUS PHARMACEUTICALS USA LLC (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240342407-A1 | INTRANASAL DESMOPRESSIN ADMINISTRATION | ACERUS PHARMACEUTICALS USA LLC (US) | 2024-10-17 | — | — | US | disclosed |
| US-12090190-B2 | Safe desmopressin administration | Acerus Pharmaceuticals USA, LLC (US) | 2024-09-17 | — | — | US | disclosed |
| WO-2024112652-A1 | COMPOSITIONS OF DRY POWDER FORMULATIONS OF MESSENGER RNA AND METHODS OF USE THEREOF | TRANSLATE BIO, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-20240024244-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | OREXO AB (SE) | 2024-01-25 | — | — | US | disclosed |
| EP-4104848-B1 | SAFE DESMOPRESSIN ADMINISTRATION | ACERUS PHARMACEUTICALS USA LLC (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023166179-A1 | IMPROVED ORAL PHARMACEUTICAL FORMULATIONS OF THERAPEUTIC PEPTIDES AND PROTEINS | CYPRUMED GMBH (AT) | 2023-09-07 | — | — | WO | disclosed |
| US-20150031614-A1 | METHODS AND COMPOSITIONS COMPRISING DESMOPRESSIN IN COMBINATION WITH A 5-ALPHA REDUCTASE INHIBITOR | FIRST GENERATION CAPITAL INC. (CA) | 2015-01-29 | — | — | US | disclosed |
| US-20120149643-A1 | Safe Desmopressin Administration | ALLERGAN, INC. | 2012-06-14 | — | — | US | disclosed |
| EP-2442821-A1 | SAFE DESMOPRESSIN ADMINISTRATION | Allergan, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| CN-102355888-A | Intranasal desmopressin administration | ALLERGAN INC | 2012-02-15 | — | — | CN | disclosed |
| US-20120015880-A1 | INTRANASAL DESMOPRESSIN ADMINISTRATION | SERENITY PHARMACEUTICALS LLC | 2012-01-19 | — | — | US | disclosed |
| EP-2381923-A2 | SAFE DESMOPRESSIN ADMINISTRATION | Allergan, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010147981-A1 | SAFE DESMOPRESSIN ADMINISTRATION | ALLERGAN, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010075327-A1 | DESMOPRESSIN COMPOSITION | SERENITY PHARMACEUTICALS CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010075266-A2 | SAFE DESMOPRESSIN ADMINISTRATION | SERENITY PHARMACEUTICALS CORPORATION (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160214-A1 | DESMOPRESSIN COMPOSITION | SERENITY PHARMACEUTICALS CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124143-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | SLC5A1, SLC5A2, GLP1R | AVPR1A 760/4885AVPR2 345/4885AVPR1B 807/4885 |
| US-20100160214-A1 | DESMOPRESSIN COMPOSITION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR2 1/4885AVPR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.